Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression

Fig. 5

Genes differentiating prospective 5-AZA responses and failures. a Expression of index fully spliced transcript (intron spliced) and alternatively spliced (intron retained) TBC1D10C transcripts in HSCs isolated prior to 5-AZA treatment in MDS and CMML patients who subsequently responded (complete response) or failed to respond (failure) to 6 cycles of treatment. Only patients from the second cohort are shown, as the first cohort was not sampled after 6 treatment cycles. MDS and CMML patients are indicated by different symbols. b Heatmap of the expression of 91 de-novo assembled transcripts in HSCs differentiating prospective treatment responses and failures. Only patients from the second cohort are shown. c Expression of genes overlapping treatment outcome-prognostic transcripts at CD34+ and CD34 progressive stages of normal haematopoietic development (MPP, multipotential progenitor; CMP, common myeloid progenitor; GMP, granulocyte monocyte progenitor; MEP, megakaryocyte-erythroid progenitor; e-PM, early promyelocyte; l-PM; late promyelocyte; MY, myelocyte; MM, metamyelocyte; BC, band cell; PMN, polymorphonuclear cell; Mono, monocyte). d Functional annotation of genes overlapping treatment outcome-prognostic transcripts, according to the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (https://david.ncifcrf.gov/home.jsp)

Back to article page